View ValuationPanacea Biotec 将来の成長Future 基準チェック /06現在、 Panacea Biotecの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長31.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change).Reported Earnings • May 31Full year 2026 earnings released: ₹0.88 loss per share (vs ₹1.37 loss in FY 2025)Full year 2026 results: ₹0.88 loss per share (improved from ₹1.37 loss in FY 2025). Revenue: ₹6.57b (up 18% from FY 2025). Net loss: ₹53.7m (loss narrowed 36% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings.お知らせ • May 23Panacea Biotec Limited to Report Q4, 2026 Results on May 29, 2026Panacea Biotec Limited announced that they will report Q4, 2026 results on May 29, 2026Reported Earnings • Feb 12Third quarter 2026 earnings released: EPS: ₹0.65 (vs ₹0.74 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.65 (down from ₹0.74 in 3Q 2025). Revenue: ₹1.67b (up 2.4% from 3Q 2025). Net income: ₹39.8m (down 12% from 3Q 2025). Profit margin: 2.4% (down from 2.8% in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 193 percentage points per year, which is a significant difference in performance.お知らせ • Feb 02Panacea Biotec Limited to Report Q3, 2026 Results on Feb 11, 2026Panacea Biotec Limited announced that they will report Q3, 2026 results on Feb 11, 2026New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.4% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).Reported Earnings • Nov 16Second quarter 2026 earnings released: ₹2.27 loss per share (vs ₹0.77 profit in 2Q 2025)Second quarter 2026 results: ₹2.27 loss per share (down from ₹0.77 profit in 2Q 2025). Revenue: ₹1.48b (flat on 2Q 2025). Net loss: ₹139.2m (down 390% from profit in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 190 percentage points per year, which is a significant difference in performance.お知らせ • Nov 04Panacea Biotec Limited to Report Q2, 2026 Results on Nov 14, 2025Panacea Biotec Limited announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Aug 18Panacea Biotec Limited, Annual General Meeting, Sep 30, 2025Panacea Biotec Limited, Annual General Meeting, Sep 30, 2025, at 11:30 Indian Standard Time.Reported Earnings • Aug 16First quarter 2026 earnings released: EPS: ₹0.66 (vs ₹2.59 loss in 1Q 2025)First quarter 2026 results: EPS: ₹0.66 (up from ₹2.59 loss in 1Q 2025). Revenue: ₹1.72b (up 49% from 1Q 2025). Net income: ₹40.5m (up ₹198.5m from 1Q 2025). Profit margin: 2.3% (up from net loss in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 182 percentage points per year, which is a significant difference in performance.お知らせ • Aug 04Panacea Biotec Limited to Report Q1, 2026 Results on Aug 14, 2025Panacea Biotec Limited announced that they will report Q1, 2026 results on Aug 14, 2025New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Jun 02Full year 2025 earnings released: ₹1.37 loss per share (vs ₹0.19 loss in FY 2024)Full year 2025 results: ₹1.37 loss per share (further deteriorated from ₹0.19 loss in FY 2024). Revenue: ₹5.59b (flat on FY 2024). Net loss: ₹83.7m (loss widened ₹72.0m from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 177 percentage points per year, which is a significant difference in performance.お知らせ • May 24Panacea Biotec Limited to Report Q4, 2025 Results on May 30, 2025Panacea Biotec Limited announced that they will report Q4, 2025 results on May 30, 2025Board Change • Apr 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Ambika Sharma was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 01Panacea Biotec Limited Announces Cessation of Narotam Kumar Juneja as Director and Chairperson / Member of the Committees of the Board of Directors, Effective March 31, 2025Panacea Biotec Limited announced that Narotam Kumar Juneja (DIN: 01204817), non-executive non-independent director of the Company was re-appointed as director liable to retire by rotation, in the Annual General Meeting ("AGM") held on September 27, 2024, for a period upto March 31, 2025. Accordingly, he has completed his tenure as non-executive non-independent director and consequently ceased to be the director of the Company on March 31, 2025. Accordingly, he has also ceased to be the Chairperson /member of the Committees of the Board of Directors of the Company. Similarly, Mr. Narotam Kumar Juneja has also completed his tenure as Whole-time Director in the Company's material subsidiary viz., Panacea Biotec Pharma Limited ("PBPL") and consequently ceased to be the director of PBPL on March 31, 2025.お知らせ • Mar 31Panacea Biotec Limited Announces Cessation of Manjula Upadhyay as Independent Director, Chairperson/Member of the Committees of the Board of DirectorPanacea Biotec Limited informed that Mrs. Manjula Upadhyay, Independent Director of the Company has completed her second and final term of five consecutive years as Independent Director on March 29, 2025 and consequently she has ceased to be the director of the Company. Accordingly, she has also ceased to be the Chairperson /member of the Committees of the Board of Directors of the Company. Mrs. Manjula Upadhyay will however continue to be non-executive independent director of the Company's material wholly-owned subsidiary company, Panacea Biotec Pharma Limited.Reported Earnings • Feb 15Third quarter 2025 earnings released: EPS: ₹0.74 (vs ₹0.37 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹0.74 (up from ₹0.37 loss in 3Q 2024). Revenue: ₹1.67b (up 11% from 3Q 2024). Net income: ₹45.2m (up ₹67.2m from 3Q 2024). Profit margin: 2.7% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.お知らせ • Jan 31Panacea Biotec Limited to Report Q3, 2025 Results on Feb 14, 2025Panacea Biotec Limited announced that they will report Q3, 2025 results on Feb 14, 2025Recent Insider Transactions • Jan 01Joint MD & Executive Director recently sold ₹6.5m worth of stockOn the 24th of December, Sandeep Jain sold around 15k shares on-market at roughly ₹435 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹29m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹189m.Recent Insider Transactions • Dec 14Joint MD & Executive Director recently sold ₹7.0m worth of stockOn the 11th of December, Sandeep Jain sold around 16k shares on-market at roughly ₹454 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹29m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹174m.Recent Insider Transactions • Dec 03Joint MD & Executive Director recently sold ₹9.5m worth of stockOn the 29th of November, Sandeep Jain sold around 23k shares on-market at roughly ₹421 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹33m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹163m.Recent Insider Transactions • Nov 24Joint MD & Executive Director recently sold ₹29m worth of stockOn the 21st of November, Sandeep Jain sold around 74k shares on-market at roughly ₹391 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹33m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹149m.Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: ₹0.77 (vs ₹1.35 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.77 (up from ₹1.35 loss in 2Q 2024). Revenue: ₹1.52b (up 6.3% from 2Q 2024). Net income: ₹48.0m (up ₹130.9m from 2Q 2024). Profit margin: 3.2% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.お知らせ • Oct 30Panacea Biotec Limited to Report Q2, 2025 Results on Nov 13, 2024Panacea Biotec Limited announced that they will report Q2, 2025 results on Nov 13, 2024お知らせ • Oct 18Panacea Biotec Limited Announces Demise of Bhupinder Singh, Independent Director, Member of the Board and CommitteePanacea Biotec Limited announced that the sad demise of Mr. Bhupinder Singh, Independent Director of the Company on October 16, 2024. Mr. Bhupinder Singh was Independent Director of the Company since April 08, 2019. During his tenure as Director on the Board, the Company has immensely benefited from his thorough knowledge and rich experience as a member of the Board and Committee thereof. The Directors and Employees of the Company convey their deep sympathy and condolences to his family.Recent Insider Transactions • Aug 23Joint MD & Executive Director recently sold ₹1.3m worth of stockOn the 20th of August, Sandeep Jain sold around 7k shares on-market at roughly ₹181 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹7.4m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹15m.New Risk • Aug 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Significant insider selling over the past 3 months (₹14m sold).Reported Earnings • Aug 15First quarter 2025 earnings released: ₹2.59 loss per share (vs ₹1.79 profit in 1Q 2024)First quarter 2025 results: ₹2.59 loss per share (down from ₹1.79 profit in 1Q 2024). Revenue: ₹1.20b (down 7.5% from 1Q 2024). Net loss: ₹158.0m (down 244% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 20% per year.お知らせ • Aug 14Panacea Biotec Limited, Annual General Meeting, Sep 27, 2024Panacea Biotec Limited, Annual General Meeting, Sep 27, 2024, at 11:30 Indian Standard Time.お知らせ • Aug 02Panacea Biotec Limited to Report Q1, 2025 Results on Aug 14, 2024Panacea Biotec Limited announced that they will report Q1, 2025 results on Aug 14, 2024Recent Insider Transactions • Jun 22Joint MD & Executive Director recently sold ₹1.3m worth of stockOn the 19th of June, Sandeep Jain sold around 10k shares on-market at roughly ₹133 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Sandeep's only on-market trade for the last 12 months.Reported Earnings • Jun 04Full year 2024 earnings released: ₹0.19 loss per share (vs ₹5.43 loss in FY 2023)Full year 2024 results: ₹0.19 loss per share (improved from ₹5.43 loss in FY 2023). Revenue: ₹5.85b (up 27% from FY 2023). Net loss: ₹11.7m (loss narrowed 97% from FY 2023). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.New Risk • May 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.15b (US$97.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.New Risk • Mar 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.28b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 15Third quarter 2024 earnings released: ₹0.37 loss per share (vs ₹3.16 profit in 3Q 2023)Third quarter 2024 results: ₹0.37 loss per share (down from ₹3.16 profit in 3Q 2023). Revenue: ₹1.51b (up 31% from 3Q 2023). Net loss: ₹22.0m (down 111% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Jan 31Panacea Biotec Limited to Report Q3, 2024 Results on Feb 13, 2024Panacea Biotec Limited announced that they will report Q3, 2024 results on Feb 13, 2024お知らせ • Dec 14Panacea Biotec Launches EasyFourPol® in India and Receives Registration of Valganciclovir Powder for Oral Solution in GermanyPanacea Biotec Limited announced the launch of world's first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol®, in India and registration of Valganciclovir 50 mg/ml Powder for Oral Solution by its step down wholly-owned subsidiary company, Panacea Biotec Germany GmbH, in Germany. EasyFourPol® is the world's first fully liquid wP-IPV Pentavalent vaccine. wP-IPV Pentavalent vaccine protects children against five deadly diseases i.e. Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b. Valganciclovir 50 mg/ml Powder for Oral Solution competes in a 1 million market (as per IQVIA). The medication is a deoxynucleoside analogue cytomegalovirus DNA polymerase inhibitor indicated for: the initial and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS). the prophylaxis of CMV disease in CMV-negative adults and children (from birth and up to 18 years of age) who have received an organ transplant from a CMV-positive donor.Reported Earnings • Nov 12Second quarter 2024 earnings released: ₹1.35 loss per share (vs ₹2.56 profit in 2Q 2023)Second quarter 2024 results: ₹1.35 loss per share (down from ₹2.56 profit in 2Q 2023). Revenue: ₹1.46b (up 39% from 2Q 2023). Net loss: ₹82.9m (down 153% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Oct 24Panacea Biotec Limited to Report Q2, 2024 Results on Nov 10, 2023Panacea Biotec Limited announced that they will report Q2, 2024 results on Nov 10, 2023New Risk • Oct 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.0% net profit margin).Valuation Update With 7 Day Price Move • Sep 18Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹165, the stock trades at a trailing P/E ratio of 30.3x. Average trailing P/E is 30x in the Biotechs industry in India. Total loss to shareholders of 16% over the past three years.New Risk • Aug 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.0% net profit margin).Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹158, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 35x in the Biotechs industry in India. Total loss to shareholders of 17% over the past three years.Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹1.79 (vs ₹9.17 loss in 1Q 2023)First quarter 2024 results: EPS: ₹1.79 (up from ₹9.17 loss in 1Q 2023). Revenue: ₹1.29b (up 17% from 1Q 2023). Net income: ₹109.8m (up ₹671.2m from 1Q 2023). Profit margin: 8.5% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Jul 30Panacea Biotec Limited to Report Q1, 2024 Results on Aug 12, 2023Panacea Biotec Limited announced that they will report Q1, 2024 results at 12:08 PM, Indian Standard Time on Aug 12, 2023Reported Earnings • May 31Full year 2023 earnings released: ₹5.51 loss per share (vs ₹176 profit in FY 2022)Full year 2023 results: ₹5.51 loss per share (down from ₹176 profit in FY 2022). Revenue: ₹5.12b (down 23% from FY 2022). Net loss: ₹337.5m (down 103% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 15Third quarter 2023 earnings released: EPS: ₹3.16 (vs ₹8.03 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹3.16 (up from ₹8.03 loss in 3Q 2022). Revenue: ₹1.15b (down 26% from 3Q 2022). Net income: ₹193.7m (up ₹685.7m from 3Q 2022). Profit margin: 17% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 19Second quarter 2023 earnings released: EPS: ₹2.56 (vs ₹8.65 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹2.56 (up from ₹8.65 loss in 2Q 2022). Revenue: ₹1.05b (down 55% from 2Q 2022). Net income: ₹157.0m (up ₹687.1m from 2Q 2022). Profit margin: 15% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. Additional Non-Executive Non-Independent Director Narotam Juneja was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 09Panacea Biotec Limited Announces Demise of Shri Soshil Kumar Jain, the Founder, ChairmanPanacea Biotec Limited announced that Shri Soshil Kumar Jain, the Founder, Chairman and the patriarch of Promoters family of the company has left for his heavenly abode on October 07, 2022. Shri Soshil Kumar Jain's sudden and unexpected passing away will be an irreparable loss to the Company and all the directors and employees of the Company convey deep sympathy, son-ow and condolences to his bereaved family members.お知らせ • Sep 07+ 3 more updatesPanacea Biotec Limited to Report Q2, 2023 Results on Nov 14, 2022Panacea Biotec Limited announced that they will report Q2, 2023 results at 3:30 PM, Indian Standard Time on Nov 14, 2022Reported Earnings • Aug 10First quarter 2023 earnings released: ₹9.17 loss per share (vs ₹9.36 loss in 1Q 2022)First quarter 2023 results: ₹9.17 loss per share (up from ₹9.36 loss in 1Q 2022). Revenue: ₹1.23b (down 7.2% from 1Q 2022). Net loss: ₹561.4m (loss narrowed 2.1% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Aug 10Panacea Biotec Limited, Annual General Meeting, Sep 28, 2022Panacea Biotec Limited, Annual General Meeting, Sep 28, 2022, at 11:30 Indian Standard Time.お知らせ • Jul 28Panacea Biotec Limited to Report Q1, 2023 Results on Aug 09, 2022Panacea Biotec Limited announced that they will report Q1, 2023 results on Aug 09, 2022Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. Additional Non-Executive Non-Independent Director Narotam Juneja was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 22Full year 2022 earnings released: EPS: ₹176 (vs ₹23.88 loss in FY 2021)Full year 2022 results: EPS: ₹176 (up from ₹23.88 loss in FY 2021). Revenue: ₹6.61b (up 5.8% from FY 2021). Net income: ₹10.8b (up ₹12.2b from FY 2021). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Board Change • May 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. Additional Non-Executive Non-Independent Director Narotam Juneja was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 03Panacea Biotec Limited Appoints Narotam Kumar Juneja as an Additional DirectorPanacea Biotec Limited appointed Mr. Narotam Kumar Juneja (DIN: 01204817) as an additional director (in the capacity of Non-Executive Non-Independent Director) on the Board of Directors of the Company with effect from April 01, 2022.Board Change • Mar 13Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 6 highly experienced directors. Non Executive Independent Director Bhupinder Singh was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 16Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: ₹8.03 loss per share (down from ₹6.54 loss in 3Q 2021). Revenue: ₹1.58b (up 11% from 3Q 2021). Net loss: ₹492.0m (loss widened 23% from 3Q 2021). Revenue missed analyst estimates by 6.7%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 85 percentage points per year, which is a significant difference in performance.Reported Earnings • Jul 24First quarter 2022 earnings released: ₹9.36 loss per share (vs ₹5.41 loss in 1Q 2021)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: ₹1.36b (up 2.2% from 1Q 2021). Net loss: ₹573.5m (loss widened 73% from 1Q 2021).お知らせ • Jul 06Panacea Biotec Announces Receipt of Manufacturing License to Produce Sputnik V Vaccine at Baddi, Himachal PradeshPanacea Biotec announced receipt of manufacturing license from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia's sovereign wealth fund). The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India. The batches produced at Panacea Biotec's facilities at Baddi, Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control. The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India. Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021. Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people. The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.Reported Earnings • Jun 04Full year 2021 earnings released: ₹23.87 loss per share (vs ₹30.67 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: ₹6.35b (up 17% from FY 2020). Net loss: ₹1.46b (loss narrowed 22% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.お知らせ • May 25The Russian Direct Investment Fund and Panacea Biotec Announce the Launch of Production of the Russian Sputnik V Vaccine Against CoronavirusThe Russian Direct Investment Fund and Panacea Biotec announced the launch of production of the Russian Sputnik V vaccine against coronavirus. The first batch produced at Panacea Biotec's facilities at Baddi will be shipped to the Gamaleya Center for quality control. Full-scale production of the vaccine is due to star this summer, Company's facilities comply with GMP standards and are prequalified by WHO. Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against coronavirus with the Russian vaccine started on May 14. As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of SputnikvV. To date Sputnik V has been registered in 66 countries globally with total population of over 3.2 billion people. Efficacy of Sputnik V is 97.6% based on the analysis of data on coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021. The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.Is New 90 Day High Low • Mar 15New 90-day low: ₹185The company is down 22% from a price of ₹238 on 15 December 2020. Underperformed the Indian market, which is up 14% over the last 90 days. Lagged the Biotechs industry, which is down 11% over the same period.Reported Earnings • Feb 13Third quarter 2021 earnings released: ₹6.54 loss per share (vs ₹3.29 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₹1.44b (down 14% from 3Q 2020). Net loss: ₹400.5m (loss widened 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 68% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.お知らせ • Feb 03Panacea Biotec Limited to Report Q3, 2021 Results on Feb 12, 2021Panacea Biotec Limited announced that they will report Q3, 2021 results on Feb 12, 2021Is New 90 Day High Low • Dec 02New 90-day high: ₹246The company is up 30% from its price of ₹189 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.Reported Earnings • Nov 12Second quarter 2021 earnings released: ₹3.09 loss per shareThe company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: ₹1.84b (up 47% from 2Q 2020). Net loss: ₹189.0m (loss narrowed 74% from 2Q 2020).お知らせ • Nov 12Panacea Biotec Limited, Annual General Meeting, Dec 24, 2020Panacea Biotec Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Indian Standard Time.Is New 90 Day High Low • Oct 16New 90-day low: ₹181The company is down 8.0% from its price of ₹196 on 17 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.お知らせ • Oct 10Panacea Biotec Limited Announces Resignation of Sunanda Jain and Mr. Sumit Jain, Whole-Time DirectorsPanacea Biotec Limited that Mrs. Sunanda Jain and Mr. Sumit Jain, Whole-time Directors of the Company, have resigned from the Board of Directors of the Company and the said resignations have become effective from 7th October, 2020.お知らせ • Oct 08Panacea Biotec Limited (BSE:531349) completed the spin-off of Radhika Heights Limited.Panacea Biotec Limited (BSE:531349) signed a memorandum of settlement to spin-off Radhika Heights Limited on August 29, 2017. Under the terms of the transaction, existing shares held by Panacea Biotec in Radhika Heights will be cancelled and Radhika Heights will issue new shares to all the shareholders of Panacea Biotec in the same proportion and the new shares of Radhika Heights will be listed on BSE and NSE. Radhika Heights will issue 2 fully paid equity shares to the equity shareholders of Panacea Biotec for every one equity share held by them in Panacea Biotec and one 0.5% cumulative non- convertible and non- participating redeemable preference share of Radhika Heights to the preference shareholders of Panacea Biotec for every 100 preference shares held by them in Panacea Biotec. Radhika Heights reported total revenues of INR 41.1 million for the financial year ended March 31, 2017. Radhika Heights Limited will be managed by Ravinder Jain. The deal is subject to approvals from the board of directors, banks, lending institutions, SEBI, NSE, BSE, shareholders, creditors and the national company law tribunal. As of February 26, 2019, the demerger has been approved by the Board of Directors of Panacea Biotec Limited. As of September 9, 2020, National Company Law Tribunal, Chandigarh Bench (“NCLT”) approved the transaction. The record date is set at September 22, 2020. Panacea Biotec Limited (BSE:531349) completed the spin-off of Radhika Heights Limited on October 6, 2020. Shareholders will receive 1 equity share in the Resulting Company, for every 1 equity share held in the Demerged Company; and 1 0.5% cumulative non-convertible and non-participating preference share in the Resulting Company for every 100 preference shares (i.e. 0.5% cumulative non-convertible and non-participating Redeemable Preference Share) held in the Demerged Company. The new Equity Shares issued & allotted by Resulting Company to the shareholders of the Demerged Company in accordance with the Scheme shall be listed and/or admitted to trading on the BSE Limited and National Stock Exchange ofIndia Limited (NSE), subject to requisite approvals of Exchanges/SEBI.お知らせ • Sep 26Panacea Biotec Limited Announces Completion of its Phase I/II Study to Evaluate the Safety and Immunogenicity of Vaccine, DengiAll, Single-Dose Live-Attenuated Tetravalent VaccinePanacea Biotec Limited announced the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose live-attenuated tetravalent vaccine. According to the World Health Organization, Dengue represents one of the ten biggest global health threats, and it is critical that have access to a safe and effective vaccine candidate that can reduce the devastating impact of Dengue fever in endemic regions. DengiAll has illustrated the strength of PanaceaBiotec's expertise in vaccinology, research, development, and manufacturing while leveraging NIH's ability to work on complex biological challenges to develop breakthrough technologies. PanaceaBiotec through continued support from National Institutes of Health, Technology Development Board, and other stakeholders is in a better position to increase affordable access to DengiAll to fight Dengue, a disease that has eluded mankind for generations. With more than 3.9 billion people living in Dengue endemic areas and over 390 million infections per year, DengiAll targets a global market of over $3 billion.お知らせ • Aug 26Panacea Biotec Limited to Report Q1, 2021 Results on Sep 03, 2020Panacea Biotec Limited announced that they will report Q1, 2021 results on Sep 03, 2020お知らせ • Jun 19Panacea Biotec Limited to Report Q4, 2020 Results on Jun 29, 2020Panacea Biotec Limited announced that they will report Q4, 2020 results on Jun 29, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Panacea Biotec は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:531349 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20266,398-54-374167N/A12/31/20256,056-78N/AN/AN/A9/30/20256,039-72-975-378N/A6/30/20256,101115N/AN/AN/A3/31/20255,591-84-777-274N/A12/31/20245,630-79N/AN/AN/A9/30/20245,500-147-177247N/A6/30/20245,457-279N/AN/AN/A3/31/20245,592-12-79435N/A12/31/20235,516-117N/AN/AN/A9/30/20235,16399-1,098-318N/A6/30/20234,784334N/AN/AN/A3/31/20234,599-332-4,634-4,225N/A12/31/20224,71812,164N/AN/AN/A9/30/20225,12411,478-5,661-5,486N/A6/30/20226,39510,791N/AN/AN/A3/31/20226,61210,783-1,210-1,084N/A12/31/20216,888-2,137N/AN/AN/A9/30/20216,746-2,0467961,072N/A6/30/20216,245-1,704N/AN/AN/A3/31/20216,248-1,4628491,067N/A12/31/20205,819-1,604N/AN/AN/A9/30/20206,079-1,405582667N/A6/30/20205,510-1,945N/AN/AN/A3/31/20205,441-1,878-371-302N/A12/31/20195,454653N/AN/AN/A9/30/20194,880715N/A-236N/A6/30/20194,832482N/AN/AN/A3/31/20194,567410N/A1,044N/A3/31/20185,928-716N/A1,180N/A3/31/20175,440-392N/A1,307N/A3/31/20166,531-183N/A907N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 531349の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 531349の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 531349の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 531349の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 531349の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 531349の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 12:59終値2026/06/11 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Panacea Biotec Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Rohit Bhat360 ONE Capital Market Private LimitedAmit Gupta360 ONE Capital Market Private LimitedArvind BothraBofA Global Research2 その他のアナリストを表示
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change).
Reported Earnings • May 31Full year 2026 earnings released: ₹0.88 loss per share (vs ₹1.37 loss in FY 2025)Full year 2026 results: ₹0.88 loss per share (improved from ₹1.37 loss in FY 2025). Revenue: ₹6.57b (up 18% from FY 2025). Net loss: ₹53.7m (loss narrowed 36% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings.
お知らせ • May 23Panacea Biotec Limited to Report Q4, 2026 Results on May 29, 2026Panacea Biotec Limited announced that they will report Q4, 2026 results on May 29, 2026
Reported Earnings • Feb 12Third quarter 2026 earnings released: EPS: ₹0.65 (vs ₹0.74 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.65 (down from ₹0.74 in 3Q 2025). Revenue: ₹1.67b (up 2.4% from 3Q 2025). Net income: ₹39.8m (down 12% from 3Q 2025). Profit margin: 2.4% (down from 2.8% in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 193 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 02Panacea Biotec Limited to Report Q3, 2026 Results on Feb 11, 2026Panacea Biotec Limited announced that they will report Q3, 2026 results on Feb 11, 2026
New Risk • Dec 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.4% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).
Reported Earnings • Nov 16Second quarter 2026 earnings released: ₹2.27 loss per share (vs ₹0.77 profit in 2Q 2025)Second quarter 2026 results: ₹2.27 loss per share (down from ₹0.77 profit in 2Q 2025). Revenue: ₹1.48b (flat on 2Q 2025). Net loss: ₹139.2m (down 390% from profit in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 190 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 04Panacea Biotec Limited to Report Q2, 2026 Results on Nov 14, 2025Panacea Biotec Limited announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Aug 18Panacea Biotec Limited, Annual General Meeting, Sep 30, 2025Panacea Biotec Limited, Annual General Meeting, Sep 30, 2025, at 11:30 Indian Standard Time.
Reported Earnings • Aug 16First quarter 2026 earnings released: EPS: ₹0.66 (vs ₹2.59 loss in 1Q 2025)First quarter 2026 results: EPS: ₹0.66 (up from ₹2.59 loss in 1Q 2025). Revenue: ₹1.72b (up 49% from 1Q 2025). Net income: ₹40.5m (up ₹198.5m from 1Q 2025). Profit margin: 2.3% (up from net loss in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 182 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 04Panacea Biotec Limited to Report Q1, 2026 Results on Aug 14, 2025Panacea Biotec Limited announced that they will report Q1, 2026 results on Aug 14, 2025
New Risk • Jul 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Jun 02Full year 2025 earnings released: ₹1.37 loss per share (vs ₹0.19 loss in FY 2024)Full year 2025 results: ₹1.37 loss per share (further deteriorated from ₹0.19 loss in FY 2024). Revenue: ₹5.59b (flat on FY 2024). Net loss: ₹83.7m (loss widened ₹72.0m from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 177 percentage points per year, which is a significant difference in performance.
お知らせ • May 24Panacea Biotec Limited to Report Q4, 2025 Results on May 30, 2025Panacea Biotec Limited announced that they will report Q4, 2025 results on May 30, 2025
Board Change • Apr 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Ambika Sharma was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 01Panacea Biotec Limited Announces Cessation of Narotam Kumar Juneja as Director and Chairperson / Member of the Committees of the Board of Directors, Effective March 31, 2025Panacea Biotec Limited announced that Narotam Kumar Juneja (DIN: 01204817), non-executive non-independent director of the Company was re-appointed as director liable to retire by rotation, in the Annual General Meeting ("AGM") held on September 27, 2024, for a period upto March 31, 2025. Accordingly, he has completed his tenure as non-executive non-independent director and consequently ceased to be the director of the Company on March 31, 2025. Accordingly, he has also ceased to be the Chairperson /member of the Committees of the Board of Directors of the Company. Similarly, Mr. Narotam Kumar Juneja has also completed his tenure as Whole-time Director in the Company's material subsidiary viz., Panacea Biotec Pharma Limited ("PBPL") and consequently ceased to be the director of PBPL on March 31, 2025.
お知らせ • Mar 31Panacea Biotec Limited Announces Cessation of Manjula Upadhyay as Independent Director, Chairperson/Member of the Committees of the Board of DirectorPanacea Biotec Limited informed that Mrs. Manjula Upadhyay, Independent Director of the Company has completed her second and final term of five consecutive years as Independent Director on March 29, 2025 and consequently she has ceased to be the director of the Company. Accordingly, she has also ceased to be the Chairperson /member of the Committees of the Board of Directors of the Company. Mrs. Manjula Upadhyay will however continue to be non-executive independent director of the Company's material wholly-owned subsidiary company, Panacea Biotec Pharma Limited.
Reported Earnings • Feb 15Third quarter 2025 earnings released: EPS: ₹0.74 (vs ₹0.37 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹0.74 (up from ₹0.37 loss in 3Q 2024). Revenue: ₹1.67b (up 11% from 3Q 2024). Net income: ₹45.2m (up ₹67.2m from 3Q 2024). Profit margin: 2.7% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 31Panacea Biotec Limited to Report Q3, 2025 Results on Feb 14, 2025Panacea Biotec Limited announced that they will report Q3, 2025 results on Feb 14, 2025
Recent Insider Transactions • Jan 01Joint MD & Executive Director recently sold ₹6.5m worth of stockOn the 24th of December, Sandeep Jain sold around 15k shares on-market at roughly ₹435 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹29m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹189m.
Recent Insider Transactions • Dec 14Joint MD & Executive Director recently sold ₹7.0m worth of stockOn the 11th of December, Sandeep Jain sold around 16k shares on-market at roughly ₹454 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹29m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹174m.
Recent Insider Transactions • Dec 03Joint MD & Executive Director recently sold ₹9.5m worth of stockOn the 29th of November, Sandeep Jain sold around 23k shares on-market at roughly ₹421 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹33m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹163m.
Recent Insider Transactions • Nov 24Joint MD & Executive Director recently sold ₹29m worth of stockOn the 21st of November, Sandeep Jain sold around 74k shares on-market at roughly ₹391 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹33m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹149m.
Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: ₹0.77 (vs ₹1.35 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.77 (up from ₹1.35 loss in 2Q 2024). Revenue: ₹1.52b (up 6.3% from 2Q 2024). Net income: ₹48.0m (up ₹130.9m from 2Q 2024). Profit margin: 3.2% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
お知らせ • Oct 30Panacea Biotec Limited to Report Q2, 2025 Results on Nov 13, 2024Panacea Biotec Limited announced that they will report Q2, 2025 results on Nov 13, 2024
お知らせ • Oct 18Panacea Biotec Limited Announces Demise of Bhupinder Singh, Independent Director, Member of the Board and CommitteePanacea Biotec Limited announced that the sad demise of Mr. Bhupinder Singh, Independent Director of the Company on October 16, 2024. Mr. Bhupinder Singh was Independent Director of the Company since April 08, 2019. During his tenure as Director on the Board, the Company has immensely benefited from his thorough knowledge and rich experience as a member of the Board and Committee thereof. The Directors and Employees of the Company convey their deep sympathy and condolences to his family.
Recent Insider Transactions • Aug 23Joint MD & Executive Director recently sold ₹1.3m worth of stockOn the 20th of August, Sandeep Jain sold around 7k shares on-market at roughly ₹181 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹7.4m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹15m.
New Risk • Aug 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Significant insider selling over the past 3 months (₹14m sold).
Reported Earnings • Aug 15First quarter 2025 earnings released: ₹2.59 loss per share (vs ₹1.79 profit in 1Q 2024)First quarter 2025 results: ₹2.59 loss per share (down from ₹1.79 profit in 1Q 2024). Revenue: ₹1.20b (down 7.5% from 1Q 2024). Net loss: ₹158.0m (down 244% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 20% per year.
お知らせ • Aug 14Panacea Biotec Limited, Annual General Meeting, Sep 27, 2024Panacea Biotec Limited, Annual General Meeting, Sep 27, 2024, at 11:30 Indian Standard Time.
お知らせ • Aug 02Panacea Biotec Limited to Report Q1, 2025 Results on Aug 14, 2024Panacea Biotec Limited announced that they will report Q1, 2025 results on Aug 14, 2024
Recent Insider Transactions • Jun 22Joint MD & Executive Director recently sold ₹1.3m worth of stockOn the 19th of June, Sandeep Jain sold around 10k shares on-market at roughly ₹133 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Sandeep's only on-market trade for the last 12 months.
Reported Earnings • Jun 04Full year 2024 earnings released: ₹0.19 loss per share (vs ₹5.43 loss in FY 2023)Full year 2024 results: ₹0.19 loss per share (improved from ₹5.43 loss in FY 2023). Revenue: ₹5.85b (up 27% from FY 2023). Net loss: ₹11.7m (loss narrowed 97% from FY 2023). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
New Risk • May 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.15b (US$97.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
New Risk • Mar 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.28b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 15Third quarter 2024 earnings released: ₹0.37 loss per share (vs ₹3.16 profit in 3Q 2023)Third quarter 2024 results: ₹0.37 loss per share (down from ₹3.16 profit in 3Q 2023). Revenue: ₹1.51b (up 31% from 3Q 2023). Net loss: ₹22.0m (down 111% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Jan 31Panacea Biotec Limited to Report Q3, 2024 Results on Feb 13, 2024Panacea Biotec Limited announced that they will report Q3, 2024 results on Feb 13, 2024
お知らせ • Dec 14Panacea Biotec Launches EasyFourPol® in India and Receives Registration of Valganciclovir Powder for Oral Solution in GermanyPanacea Biotec Limited announced the launch of world's first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol®, in India and registration of Valganciclovir 50 mg/ml Powder for Oral Solution by its step down wholly-owned subsidiary company, Panacea Biotec Germany GmbH, in Germany. EasyFourPol® is the world's first fully liquid wP-IPV Pentavalent vaccine. wP-IPV Pentavalent vaccine protects children against five deadly diseases i.e. Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b. Valganciclovir 50 mg/ml Powder for Oral Solution competes in a 1 million market (as per IQVIA). The medication is a deoxynucleoside analogue cytomegalovirus DNA polymerase inhibitor indicated for: the initial and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS). the prophylaxis of CMV disease in CMV-negative adults and children (from birth and up to 18 years of age) who have received an organ transplant from a CMV-positive donor.
Reported Earnings • Nov 12Second quarter 2024 earnings released: ₹1.35 loss per share (vs ₹2.56 profit in 2Q 2023)Second quarter 2024 results: ₹1.35 loss per share (down from ₹2.56 profit in 2Q 2023). Revenue: ₹1.46b (up 39% from 2Q 2023). Net loss: ₹82.9m (down 153% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Oct 24Panacea Biotec Limited to Report Q2, 2024 Results on Nov 10, 2023Panacea Biotec Limited announced that they will report Q2, 2024 results on Nov 10, 2023
New Risk • Oct 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.0% net profit margin).
Valuation Update With 7 Day Price Move • Sep 18Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹165, the stock trades at a trailing P/E ratio of 30.3x. Average trailing P/E is 30x in the Biotechs industry in India. Total loss to shareholders of 16% over the past three years.
New Risk • Aug 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.0% net profit margin).
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹158, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 35x in the Biotechs industry in India. Total loss to shareholders of 17% over the past three years.
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹1.79 (vs ₹9.17 loss in 1Q 2023)First quarter 2024 results: EPS: ₹1.79 (up from ₹9.17 loss in 1Q 2023). Revenue: ₹1.29b (up 17% from 1Q 2023). Net income: ₹109.8m (up ₹671.2m from 1Q 2023). Profit margin: 8.5% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Jul 30Panacea Biotec Limited to Report Q1, 2024 Results on Aug 12, 2023Panacea Biotec Limited announced that they will report Q1, 2024 results at 12:08 PM, Indian Standard Time on Aug 12, 2023
Reported Earnings • May 31Full year 2023 earnings released: ₹5.51 loss per share (vs ₹176 profit in FY 2022)Full year 2023 results: ₹5.51 loss per share (down from ₹176 profit in FY 2022). Revenue: ₹5.12b (down 23% from FY 2022). Net loss: ₹337.5m (down 103% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 15Third quarter 2023 earnings released: EPS: ₹3.16 (vs ₹8.03 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹3.16 (up from ₹8.03 loss in 3Q 2022). Revenue: ₹1.15b (down 26% from 3Q 2022). Net income: ₹193.7m (up ₹685.7m from 3Q 2022). Profit margin: 17% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 19Second quarter 2023 earnings released: EPS: ₹2.56 (vs ₹8.65 loss in 2Q 2022)Second quarter 2023 results: EPS: ₹2.56 (up from ₹8.65 loss in 2Q 2022). Revenue: ₹1.05b (down 55% from 2Q 2022). Net income: ₹157.0m (up ₹687.1m from 2Q 2022). Profit margin: 15% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. Additional Non-Executive Non-Independent Director Narotam Juneja was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 09Panacea Biotec Limited Announces Demise of Shri Soshil Kumar Jain, the Founder, ChairmanPanacea Biotec Limited announced that Shri Soshil Kumar Jain, the Founder, Chairman and the patriarch of Promoters family of the company has left for his heavenly abode on October 07, 2022. Shri Soshil Kumar Jain's sudden and unexpected passing away will be an irreparable loss to the Company and all the directors and employees of the Company convey deep sympathy, son-ow and condolences to his bereaved family members.
お知らせ • Sep 07+ 3 more updatesPanacea Biotec Limited to Report Q2, 2023 Results on Nov 14, 2022Panacea Biotec Limited announced that they will report Q2, 2023 results at 3:30 PM, Indian Standard Time on Nov 14, 2022
Reported Earnings • Aug 10First quarter 2023 earnings released: ₹9.17 loss per share (vs ₹9.36 loss in 1Q 2022)First quarter 2023 results: ₹9.17 loss per share (up from ₹9.36 loss in 1Q 2022). Revenue: ₹1.23b (down 7.2% from 1Q 2022). Net loss: ₹561.4m (loss narrowed 2.1% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Aug 10Panacea Biotec Limited, Annual General Meeting, Sep 28, 2022Panacea Biotec Limited, Annual General Meeting, Sep 28, 2022, at 11:30 Indian Standard Time.
お知らせ • Jul 28Panacea Biotec Limited to Report Q1, 2023 Results on Aug 09, 2022Panacea Biotec Limited announced that they will report Q1, 2023 results on Aug 09, 2022
Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. Additional Non-Executive Non-Independent Director Narotam Juneja was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 22Full year 2022 earnings released: EPS: ₹176 (vs ₹23.88 loss in FY 2021)Full year 2022 results: EPS: ₹176 (up from ₹23.88 loss in FY 2021). Revenue: ₹6.61b (up 5.8% from FY 2021). Net income: ₹10.8b (up ₹12.2b from FY 2021). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Board Change • May 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. Additional Non-Executive Non-Independent Director Narotam Juneja was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 03Panacea Biotec Limited Appoints Narotam Kumar Juneja as an Additional DirectorPanacea Biotec Limited appointed Mr. Narotam Kumar Juneja (DIN: 01204817) as an additional director (in the capacity of Non-Executive Non-Independent Director) on the Board of Directors of the Company with effect from April 01, 2022.
Board Change • Mar 13Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 6 highly experienced directors. Non Executive Independent Director Bhupinder Singh was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 16Third quarter 2022 earnings: EPS in line with expectations, revenues disappointThird quarter 2022 results: ₹8.03 loss per share (down from ₹6.54 loss in 3Q 2021). Revenue: ₹1.58b (up 11% from 3Q 2021). Net loss: ₹492.0m (loss widened 23% from 3Q 2021). Revenue missed analyst estimates by 6.7%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 85 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jul 24First quarter 2022 earnings released: ₹9.36 loss per share (vs ₹5.41 loss in 1Q 2021)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: ₹1.36b (up 2.2% from 1Q 2021). Net loss: ₹573.5m (loss widened 73% from 1Q 2021).
お知らせ • Jul 06Panacea Biotec Announces Receipt of Manufacturing License to Produce Sputnik V Vaccine at Baddi, Himachal PradeshPanacea Biotec announced receipt of manufacturing license from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia's sovereign wealth fund). The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India. The batches produced at Panacea Biotec's facilities at Baddi, Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control. The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India. Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021. Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people. The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
Reported Earnings • Jun 04Full year 2021 earnings released: ₹23.87 loss per share (vs ₹30.67 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: ₹6.35b (up 17% from FY 2020). Net loss: ₹1.46b (loss narrowed 22% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
お知らせ • May 25The Russian Direct Investment Fund and Panacea Biotec Announce the Launch of Production of the Russian Sputnik V Vaccine Against CoronavirusThe Russian Direct Investment Fund and Panacea Biotec announced the launch of production of the Russian Sputnik V vaccine against coronavirus. The first batch produced at Panacea Biotec's facilities at Baddi will be shipped to the Gamaleya Center for quality control. Full-scale production of the vaccine is due to star this summer, Company's facilities comply with GMP standards and are prequalified by WHO. Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against coronavirus with the Russian vaccine started on May 14. As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of SputnikvV. To date Sputnik V has been registered in 66 countries globally with total population of over 3.2 billion people. Efficacy of Sputnik V is 97.6% based on the analysis of data on coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021. The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
Is New 90 Day High Low • Mar 15New 90-day low: ₹185The company is down 22% from a price of ₹238 on 15 December 2020. Underperformed the Indian market, which is up 14% over the last 90 days. Lagged the Biotechs industry, which is down 11% over the same period.
Reported Earnings • Feb 13Third quarter 2021 earnings released: ₹6.54 loss per share (vs ₹3.29 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₹1.44b (down 14% from 3Q 2020). Net loss: ₹400.5m (loss widened 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 68% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 03Panacea Biotec Limited to Report Q3, 2021 Results on Feb 12, 2021Panacea Biotec Limited announced that they will report Q3, 2021 results on Feb 12, 2021
Is New 90 Day High Low • Dec 02New 90-day high: ₹246The company is up 30% from its price of ₹189 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.
Reported Earnings • Nov 12Second quarter 2021 earnings released: ₹3.09 loss per shareThe company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: ₹1.84b (up 47% from 2Q 2020). Net loss: ₹189.0m (loss narrowed 74% from 2Q 2020).
お知らせ • Nov 12Panacea Biotec Limited, Annual General Meeting, Dec 24, 2020Panacea Biotec Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Indian Standard Time.
Is New 90 Day High Low • Oct 16New 90-day low: ₹181The company is down 8.0% from its price of ₹196 on 17 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.
お知らせ • Oct 10Panacea Biotec Limited Announces Resignation of Sunanda Jain and Mr. Sumit Jain, Whole-Time DirectorsPanacea Biotec Limited that Mrs. Sunanda Jain and Mr. Sumit Jain, Whole-time Directors of the Company, have resigned from the Board of Directors of the Company and the said resignations have become effective from 7th October, 2020.
お知らせ • Oct 08Panacea Biotec Limited (BSE:531349) completed the spin-off of Radhika Heights Limited.Panacea Biotec Limited (BSE:531349) signed a memorandum of settlement to spin-off Radhika Heights Limited on August 29, 2017. Under the terms of the transaction, existing shares held by Panacea Biotec in Radhika Heights will be cancelled and Radhika Heights will issue new shares to all the shareholders of Panacea Biotec in the same proportion and the new shares of Radhika Heights will be listed on BSE and NSE. Radhika Heights will issue 2 fully paid equity shares to the equity shareholders of Panacea Biotec for every one equity share held by them in Panacea Biotec and one 0.5% cumulative non- convertible and non- participating redeemable preference share of Radhika Heights to the preference shareholders of Panacea Biotec for every 100 preference shares held by them in Panacea Biotec. Radhika Heights reported total revenues of INR 41.1 million for the financial year ended March 31, 2017. Radhika Heights Limited will be managed by Ravinder Jain. The deal is subject to approvals from the board of directors, banks, lending institutions, SEBI, NSE, BSE, shareholders, creditors and the national company law tribunal. As of February 26, 2019, the demerger has been approved by the Board of Directors of Panacea Biotec Limited. As of September 9, 2020, National Company Law Tribunal, Chandigarh Bench (“NCLT”) approved the transaction. The record date is set at September 22, 2020. Panacea Biotec Limited (BSE:531349) completed the spin-off of Radhika Heights Limited on October 6, 2020. Shareholders will receive 1 equity share in the Resulting Company, for every 1 equity share held in the Demerged Company; and 1 0.5% cumulative non-convertible and non-participating preference share in the Resulting Company for every 100 preference shares (i.e. 0.5% cumulative non-convertible and non-participating Redeemable Preference Share) held in the Demerged Company. The new Equity Shares issued & allotted by Resulting Company to the shareholders of the Demerged Company in accordance with the Scheme shall be listed and/or admitted to trading on the BSE Limited and National Stock Exchange ofIndia Limited (NSE), subject to requisite approvals of Exchanges/SEBI.
お知らせ • Sep 26Panacea Biotec Limited Announces Completion of its Phase I/II Study to Evaluate the Safety and Immunogenicity of Vaccine, DengiAll, Single-Dose Live-Attenuated Tetravalent VaccinePanacea Biotec Limited announced the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose live-attenuated tetravalent vaccine. According to the World Health Organization, Dengue represents one of the ten biggest global health threats, and it is critical that have access to a safe and effective vaccine candidate that can reduce the devastating impact of Dengue fever in endemic regions. DengiAll has illustrated the strength of PanaceaBiotec's expertise in vaccinology, research, development, and manufacturing while leveraging NIH's ability to work on complex biological challenges to develop breakthrough technologies. PanaceaBiotec through continued support from National Institutes of Health, Technology Development Board, and other stakeholders is in a better position to increase affordable access to DengiAll to fight Dengue, a disease that has eluded mankind for generations. With more than 3.9 billion people living in Dengue endemic areas and over 390 million infections per year, DengiAll targets a global market of over $3 billion.
お知らせ • Aug 26Panacea Biotec Limited to Report Q1, 2021 Results on Sep 03, 2020Panacea Biotec Limited announced that they will report Q1, 2021 results on Sep 03, 2020
お知らせ • Jun 19Panacea Biotec Limited to Report Q4, 2020 Results on Jun 29, 2020Panacea Biotec Limited announced that they will report Q4, 2020 results on Jun 29, 2020